Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670425 | 0.83 | KMT2A (0.43) | KMT2AMEN1MAPTIDO1TDO2 | |
| SCHEMBL4673681 | 0.80 | KMT2A (0.54) | KMT2AMEN1MAPTIDO1TDO2 | |
| SCHEMBL4673671 | 0.79 | SIGMAR1 (0.52) | KMT2AMEN1MAPTIDO1TDO2 | |
| SCHEMBL4670427 | 0.79 | ADORA2B (0.41) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4676105 | 0.78 | PKM (0.46) | KMT2AMEN1MAPTIDO1TDO2 | |
| SCHEMBL4675660 | 0.78 | ROCK2 (0.56) | KMT2AMEN1MAPTIDO1TDO2 | |
| Hydrochloric Acid SCHEMBL9384727 | 0.78 | ADORA2B (0.40) | KMT2AMEN1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4672275 | 0.77 | ALDH1A1 (0.44) | KMT2AMEN1MAPTIDO1TDO2 | |
| SCHEMBL4672086 | 0.77 | KCNJ1 (0.53) | KMT2AMEN1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL4675267 | 0.76 | ALDH1A1 (0.41) | KMT2AMEN1MAPTIDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054881-B1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-6903218-B2 | Sulfonamide substituted chroman derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | LADOUCEUR GAETAN H (US) | 2004-04-15 | — | — | US | disclosed |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | BAYER PHARMACEUTICALS CORPORATION | 2003-04-17 | — | — | US | disclosed |
| EP-1054881-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6051586-A | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | BAYER CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999032475-A1 | NOVEL SULFONAMIDE SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
| EP-0331232-B1 | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols | JANSSEN PHARMACEUTICA NV (BE) | 1994-05-18 | — | — | EP | disclosed |
| US-4931444-A | FOR LEUKOTRIENE-MEDIATED DISEASES AND DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-05 | — | — | US | disclosed |
| EP-0331232-A2 | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072843-A1 | Novel sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB2, ADRB1 | KMT2A 2831/4885MEN1 3597/4885MAPT 3838/4885 |
| US-20030073839-A1 | Compounds useful for preparation of Beta-3 adrenoreceptor agonist | ADRB3, ADRB2, ADRB1 | KMT2A 3979/4885MEN1 3337/4885MAPT 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.